Nonalcoholic Steatohepatitis: Pathologic Features and Differential Diagnosis

Overview

Journal Semin Diagn Pathol

Date 2006 Aug 31

PMID 16939061

Citations 29

Authors

Elizabeth M Brunt

Affiliations

Soon will be listed here.

Abstract

The worldwide epidemic of obesity has raised the awareness of nonalcoholic fatty liver disease (NAFLD) from that of a curiosity to one of a potentially progressive liver disease with risk for cirrhosis and hepatocellular carcinoma. This overview is focused on the histopathology of the spectrum of fatty liver disease, and discusses the role of liver biopsy, differential diagnoses, and new techniques in development. When pertinent, pathophysiology of this metabolic liver disease and recent treatment considerations have been mentioned as well.

Citing Articles

The role of SPARC (secreted protein acidic and rich in cysteine) in the pathogenesis of obesity, type 2 diabetes, and non-alcoholic fatty liver disease.

Atorrasagasti C, Onorato A, Mazzolini G J Physiol Biochem. 2022; 79(4):815-831.

PMID: 36018492 DOI: 10.1007/s13105-022-00913-5.

Lactational delivery of Triclosan promotes non-alcoholic fatty liver disease in newborn mice.

Weber A, Yang X, Mennillo E, Ding J, Watrous J, Jain M Nat Commun. 2022; 13(1):4346.

PMID: 35896521 PMC: 9329322. DOI: 10.1038/s41467-022-31947-4.

Schisandrin B ameliorates non-alcoholic liver disease through anti-inflammation activation in diabetic mice.

Ma R, Zhan Y, Zhang Y, Wu L, Wang X, Guo M Drug Dev Res. 2021; 83(3):735-744.

PMID: 34927282 PMC: 9299884. DOI: 10.1002/ddr.21905.

Portal Vein Thrombosis in Non-Cirrhotic Non-Alcoholic Fatty Liver Disease: A 9-Year Prospective Cohort Study.

Abdel-Razik A, Mousa N, Shabana W, Yassen A, Abdelsalam M, Wahba M Front Med (Lausanne). 2021; 8:650818.

PMID: 33996858 PMC: 8117420. DOI: 10.3389/fmed.2021.650818.

Non-alcoholic fatty liver diseases: current challenges and future directions.

Roeb E Ann Transl Med. 2021; 9(8):726.

PMID: 33987424 PMC: 8106107. DOI: 10.21037/atm-20-3760.